©NIJRMS
Publications 2025

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES (NIJRMS)

Volume 7 Issue 1 Page 87-94, 2026

https://doi.org/10.59298/NIJRMS/2026/7.1.8794

Nanotechnology-Driven Modulation of Adipose Tissue Browning: Therapeutic Implications for Obesity-Associated Type 2 Diabetes

Wambui Kibibi J.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

Obesity-associated type 2 diabetes (T2D) arises from chronic positive energy balance, adipose tissue dysfunction, low-grade inflammation, and insulin resistance. Converting energy-storing white adipose tissue into thermogenically active beige/brown–like adipocytes "browning"offers a compelling means to increase energy expenditure and improve glucose homeostasis by elevating uncoupling protein-1 (UCP1)–dependent respiration and mitochondrial biogenesis. Yet pharmacologic agents that induce browning often suffer from poor bioavailability, off-target toxicity, and inadequate delivery to adipose depots. Nanotechnology enables precise spatiotemporal control over therapeutic cargoes, including small molecules, peptides, and nucleic acids, while exploiting tissue-specific targeting, controlled release, and stimuli-responsiveness. Here, we review design principles for adipose-directed nanomedicines that activate thermogenic pathways; emerging nucleic acid strategies that reprogram adipocyte fate; small-molecule and nutraceutical payloads formulated for enhanced efficacy; and imaging modalities and biomarkers that quantify browning in vivo. We also consider safety, manufacturing, and regulatory issues that must be overcome for translation, and propose pragmatic clinical trial frameworks tailored to metabolic endpoints. By integrating materials science with adipose biology, nanotechnology can turn browning from a laboratory phenomenon into a clinically actionable modality for T2D, potentially complementing lifestyle interventions and incretin-based therapies while minimizing cardiovascular and sympathetic side effects.

Keywords: adipose browning; beige adipocytes; nanomedicine; targeted delivery; UCP1; insulin resistance; type 2 diabetes; nucleic acid therapeutics; β3-adrenergic signaling; thermogenesis

INTRODUCTION

Type 2 diabetes (T2D) affects hundreds of millions of people and is intimately tied to excess adiposity and sedentary lifestyles[1–3]. The pathophysiology involves impaired insulin signaling in muscle and liver, ectopic lipid deposition, and adipose tissue dysfunction marked by hypertrophy, hypoxia, and the secretion of proinflammatory adipokines[4–6]. Therapeutic strategies that merely suppress appetite or increase insulin secretion have improved glycemic control and cardiovascular outcomes for many patients, yet they do not fully correct the energetic and endocrine defects of dysfunctional white adipose tissue (WAT)[7–9]. An alternative, complementary approach is to increase whole-body energy expenditure and metabolic flexibility by converting WAT to a more oxidative, mitochondria-rich "beige" state, a process commonly termed browning.

Browning reflects the emergence of inducible beige adipocytes within WAT depots that express UCP1, a mitochondrial inner membrane protein that uncouples oxidative phosphorylation, dissipating the proton gradient as heat and thereby increasing substrate oxidation[10, 11]. Cold exposure and β-adrenergic stimulation are canonical browning triggers, but immune mediators, endocrine factors (irisin, FGF21), and nutrient signals also contribute. In preclinical models, enhanced browning improves glucose tolerance, increases insulin sensitivity, and reduces hepatic steatosis. However, direct pharmacologic activation has been constrained by systemic side effects, particularly when using β-agonists that elevate heart rate and blood pressure, and by

the limited ability of many agents to reach adipose depots at efficacious concentrations without off-target toxicity.

Nanotechnology offers a powerful toolkit to breach these barriers. Nanocarriers lipid nanoparticles, polymeric micelles, dendrimers, protein-based cages, and inorganic platforms can encapsulate diverse payloads, shield them from degradation, and release them in response to environmental cues such as pH, enzymes, or reactive oxygen species[12–15]. Surface engineering with ligands that recognize adipose endothelium, macrophages, or adipocyte receptors can enrich delivery to subcutaneous or visceral fat. Size and stiffness can be tuned to favor lymphatic drainage or vascular extravasation, and stealth coatings can prolong circulation while minimizing immune clearance. For nucleic acid therapeutics, siRNA, antisense oligos, mRNA, and programmable editors nanocarriers are not merely helpful but essential to achieve intracellular delivery.

In the specific context of browning, nanotechnology enables three complementary strategies. First, it enhances the therapeutic index of small molecules that induce thermogenesis, allowing lower systemic exposure while sustaining depot-level concentration[16]. Second, it delivers nucleic acids that reprogram adipocyte gene networks toward a beige phenotype, for example, by silencing repressors or expressing master regulators of mitochondrial biogenesis. Third, it enables combination therapies, co-packaging agents that target adipocytes and immunomodulators that shift tissue macrophages toward pro-thermogenic phenotypes, recognizing that adipose is an immunometabolic organ.

Translation requires rigorous measurement. Noninvasive imaging, including positron emission tomography, magnetic resonance techniques, and emerging optical approaches, can quantify depot-specific metabolic changes, while circulating markers and transcriptomic signatures provide orthogonal readouts[17, 18]. Safety remains central: nanocarriers must avoid chronic tissue accumulation, complement activation, and genotoxicity, and manufacturing must scale with reproducible particle attributes and release kinetics.

This review synthesizes design principles for adipose-targeted nanomedicines, surveys nucleic acid and small-molecule payloads that promote browning, and outlines state-of-the-art methods for monitoring efficacy. We evaluate safety, regulatory, and ethical considerations, and conclude with clinically oriented trial designs that integrate glycemic endpoints with imaging and cardiometabolic risk. As incretin-based therapies and metabolic surgery set new standards for efficacy, nanotechnology-enabled browning may find its niche as an adjunct that improves insulin sensitivity, increases energy expenditure, and addresses adipose dysfunction at its root.

2. Design Principles of Nanocarriers for Thermogenic Pathway Targeting

Successful adipose-directed nanomedicines arise from deliberate engineering of size, shape, surface chemistry, and release kinetics[19, 20]. Particles between ~50–150 nm often achieve favorable circulation with sufficient extravasation across adipose microvasculature, while ultra-small constructs (<20 nm) may be rapidly cleared and larger particles (>200 nm) risk uptake by the mononuclear phagocyte system. Spherical morphologies are widely used for manufacturability, but rod-like or discoidal geometries can modulate margination and endothelial interactions. Poly(ethylene glycol) coatings reduce opsonization; zwitterionic shells offer an alternative stealth strategy with lower anti-PEG immunogenicity risks[21–23].

Targeting ligands increases depot specificity. Short peptides selected by in vivo phage display can home to white or brown fat vasculature, whereas antibodies or aptamers can engage adipocyte receptors or transporters. For example, motifs against prohibitin, αvβ3 integrin, or scavenger receptors on stromal cells can enrich uptake[24–27]. Because visceral and subcutaneous depots differ in endothelium and innervation, depot-preferential targeting is feasible and clinically relevant given the cardiometabolic burden of visceral fat.

Endosomal escape is a core challenge for nucleic acid cargoes. Ionizable lipids that protonate in endosomes promote membrane destabilization and cytosolic delivery, while pH-sensitive polymers and helper lipids refine this process[19, 28, 29]. For small molecules, controlling burst versus sustained release is crucial to avoid sympathetic spikes; biodegradable polymer matrices and crystalline lipid cores provide week-scale release profiles. Stimuli-responsive designs such as pH, enzyme, redox, or ultrasound-triggered, add an extra layer of control tailored to adipose microenvironments characterized by lipase activity, mild hypoxia, and oxidative stress[30–32].

Manufacturability and analytics determine translational credibility. Scalable microfluidic or in-line solvent displacement methods yield narrow polydispersity and reproducible encapsulation efficiencies. Critical quality attributes include particle size distribution, zeta potential, residual solvent, endotoxin levels, and batch-to-batch drift in release kinetics[19]. Stability-indicating assays and physiologically relevant dissolution studies should model realistic depot exposure, including lipoprotein exchange. Sterility assurance and low bioburden are nonnegotiable for parenteral products, and lyophilization or spray-drying with cryoprotectants extends shelf life.

Finally, pharmacology in metabolic disease differs from oncology or rare-disease contexts. Obese patients may display altered lipoprotein profiles, expanded distribution volumes, and inflamed adipose tissue that modifies nanoparticle uptake[33]. Preclinical screening should therefore include diet-induced obese models, female and male cohorts, and aged animals, with telemetry and metabolic cage phenotyping. Together, these design principles integrate biophysics and disease biology to give nanocarriers the best chance of safely and effectively activating thermogenic pathways.

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

3. Nucleic Acid Nanotherapeutics for Beige Adipocyte

Nucleic acids enable precise, programmable manipulation of adipocyte gene networks central to browning. siRNA and antisense oligonucleotides can suppress inhibitory microRNAs such as miR-133 and miR-27 that restrain PRDM16 and PGC-1α, respectively, facilitating beige differentiation[34]. Conversely, mRNA delivery of PRDM16, PGC-1α, or EBF2 transiently elevates transcriptional programs for mitochondrial biogenesis, oxidative phosphorylation, and UCP1 expression without permanent genomic alteration. Lipid nanoparticles with ionizable lipids and endosomal-disruptive helpers remain the leading delivery vehicles; chemical modifications to nucleic acids (2′-O-methyl, phosphorothioate linkages) balance stability with innate immune recognition[34].

Gene editing expands the horizon but raises permanency and safety considerations. Base editors or CRISPR interference systems packaged in nanoparticles can downregulate thermogenesis repressors or enhance enhancer activity at loci governing oxidative metabolism[34]. In adipose, nonviral delivery is attractive to avoid vector persistence; however, editing efficiency, depot specificity, and off-target analysis must be rigorously quantified. For translational prudence, transient approaches like siRNA or mRNA may reach the clinic earlier, especially when combined with depot-targeted formulations to minimize dose.

Cellular heterogeneity matters. Stromal vascular fraction cells include progenitors that can differentiate into beige adipocytes under the influence of PRDM16 and sympathetic cues. Delivering nucleic acids to these progenitors may yield durable browning by expanding beige cell numbers, whereas mature adipocyte transfection primarily enhances thermogenic function per cell[35]. Single-cell transcriptomics guides ligand selection for targeting progenitor markers and avoids excessive uptake by resident macrophages unless co-opted for immunomodulation.

Safety and manufacturability are intertwined. Minimizing innate immune activation through careful sequence selection, endotoxin control, and particle purity reduces cytokine surges. Re-dosing is likely required for mRNA or siRNA; anti-PEG antibodies and complement activation–related pseudoallergy must be monitored, motivating alternative stealth chemistries[35]. Stability under refrigerated or frozen conditions and robust potency assays quantifying UCP1 or oxygen consumption in human adipocytes support quality control.

Clinically, nucleic acid strategies could be positioned as adjuncts to lifestyle and incretin therapy in patients with insulin-resistant obesity, particularly those with intolerance to systemic sympathomimetics[35]. Early trials will benefit from depot-targeted administration and imaging-supported pharmacodynamics, establishing that molecular reprogramming translates to increased thermogenic activity and improved glucose metrics without adverse cardiovascular signals.

4. Small-Molecule and Nutraceutical Payloads in Nanoparticles to Promote Browning

Small molecules that stimulate thermogenesis span β3-adrenergic agonists, PPAR modulators, thyroid hormone analogs, AMPK activators, and natural products influencing mitochondrial function. Encapsulation in nanoparticles can reconcile efficacy with safety by moderating peak systemic exposure and privileging adipose delivery[36]. For β3 agonists, nanoformulation aims to minimize heart-rate elevations by sustaining low, depot-restricted concentrations that nonetheless upregulate UCP1 and PGC-1α. PPARγ partial agonists and dual PPARα/δ modulators can improve insulin sensitivity and fatty acid oxidation; nanoencapsulation may limit edema and weight gain sometimes associated with systemic exposure by reducing off-target engagement in kidney and heart[37].

Nutraceuticals and phytochemicals, such as capsaicin, resveratrol, quercetin, berberine, and curcumin, exhibit poor solubility and rapid metabolism that blunt clinical impact. Polymeric micelles and solid lipid nanoparticles increase bioavailability and stabilize labile compounds, enabling meaningful adipose exposure[38]. Some compounds act indirectly by activating AMPK or sirtuins, strengthening mitochondrial biogenesis and thermogenic gene programs. Co-delivery strategies marry a thermogenic small molecule with an anti-inflammatory or antioxidant payload, acknowledging that inflamed adipose resists browning and that oxidative stress can undermine mitochondrial quality.

Mitochondrial uncouplers deserve special caution. While mild uncoupling increases energy expenditure, systemic exposure carries hepatotoxic and hyperthermia risks. Adipose-targeted prodrugs that are activated by local lipases or reductive environments can confine activity to WAT or beige adipocytes, and nanoparticles add a kinetic barrier against rapid release. Incorporating thermal- or ultrasound-triggered release provides an external control knob for dose titration during imaging-guided interventions[39].

Pharmacokinetics and pharmacodynamics must be co-optimized. Nanoformulations alter absorption and distribution; thus, traditional dose conversion may be misleading. Measuring depot drug levels, thermogenic gene induction, and oxygen consumption together with ambulatory cardiovascular monitoring provides a safety-efficacy map[40–42]. Combination with GLP-1/GIP receptor agonists is conceptually attractive: incretins reduce appetite and weight, while browning increases energy expenditure and insulin sensitivity. Nanocarriers can ensure that any sympathomimetic component remains localized, avoiding additive cardiovascular load.

Ultimately, small-molecule nanoformulations can translate faster than gene-based approaches owing to clearer regulatory precedents, provided they deliver tangible metabolic benefits without systemic side effects. Their success will hinge on rigorous formulation science, depot targeting, and integration with existing standards of care.

5. Imaging, Biomarkers, and Noninvasive Assessment of Browning

Quantifying browning in vivo is essential for dose selection, go/no-go decisions, and regulatory acceptance. 18F-FDG PET/CT has been the workhorse for visualizing metabolically active brown adipose tissue, especially in the supraclavicular region; however, glucose uptake does not perfectly correlate with thermogenesis, particularly under fasting or incretin-treated conditions[43]. Alternative tracers targeting fatty acid uptake, mitochondrial membrane potential, or UCP1 activity may provide more specific readouts. Magnetic resonance techniques—chemical shift–encoded MRI, proton density fat fraction mapping, and 31P/13C spectroscopy—characterize lipid content, mitochondrial metabolites, and perfusion without ionizing radiation and can be repeated longitudinally to track depot remodeling[43].

Thermography and infrared imaging detect superficial heat but lack depth penetration; pairing them with perfusion MRI or PET increases interpretability. Ultrasound elastography and photoacoustic imaging are emerging complements, potentially reflecting microvascular changes accompanying browning. For clinical trials, multimodal imaging protocols that include at least one quantitative metabolic modality and one structural modality reduce false negatives and aid dose optimization.

Circulating biomarkers help bridge imaging to metabolic outcomes. Candidates include FGF21, irisin, and BMP8B, as well as exosomal microRNAs associated with beige adipocyte programs. However, systemic concentrations are influenced by liver and muscle, necessitating composite panels that also capture inflammatory tone (e.g., high-sensitivity CRP), lipid flux (ketone bodies, free fatty acids), and insulin sensitivity (Matsuda index, HOMA-IR). In adipose biopsies used sparingly for safety, transcriptomic signatures of beige activation, mitochondrial DNA copy number, and histologic evidence of multilocular adipocytes provide gold-standard confirmation[44].

Wearable sensors add ecological validity. Resting energy expenditure estimated by indirect calorimetry, coupled with accelerometry, heart-rate variability, and skin temperature profiles, helps disentangle thermogenesis from activity-induced energy use. For safety, ambulatory blood pressure and arrhythmia monitoring are prudent when any sympathetic pathway is engaged[45]. A practical framework for trials includes a run-in phase standardizing ambient temperature and diet, baseline imaging to quantify depot activity, and predefined imaging pharmacodynamic endpoints linked to glycemic outcomes such as fasting glucose, HbA1c, and continuous glucose monitoring profiles. Such integrated assessment demonstrates that a nanotherapy not only changes imaging signals but also improves parameters central to T2D care.

6. Safety, Translational Barriers, and Regulatory/Ethical Considerations

Safety underpins every nanomedicine advance. Materials must avoid acute infusion reactions, complement activation, and delayed hypersensitivity, while limiting chronic accumulation in the liver and spleen[46]. Thorough characterization of impurities, residual solvents, and endotoxin is essential. Re-dosing studies should evaluate anti-PEG or anti-polymer antibody formation and its effect on pharmacokinetics and efficacy. For nucleic acid cargoes, innate immune activation and off-target gene regulation require careful sequence selection, bioinformatic screening, and in vivo cytokine profiling[47, 48]. Cardiac safety QT interval, heart rate, and blood pressure must be tracked continuously when pathways intersect with adrenergic signaling.

Manufacturing scale-up is a nontrivial hurdle. Batch reproducibility of particle size, encapsulation efficiency, and release kinetics must be demonstrated under GMP, with stability programs that include real-time and accelerated conditions[49]. Analytical methods need to be stability-indicating and sensitive to polymorphic transitions in lipid matrices or aggregation of polymeric systems. For combination products, interactions between co-encapsulated agents can alter release and must be modeled[49].

Regulatory pathways vary by modality. Small-molecule nanoformulations often follow 505(b)(2) or hybrid routes if the active ingredient has prior human experience, whereas gene-based nanoparticles align with advanced therapy frameworks requiring robust risk mitigation[50, 51]. Regulators will expect mechanistic biomarkers linking depot exposure to thermogenesis and metabolic improvements, not merely weight loss. Ethical considerations include equitable access and the imperative to avoid framing obesity solely as a personal responsibility rather than a complex, socio-environmental disease.

Environmental impact should not be neglected. The lifecycle of nanomaterials from synthesis to disposal must minimize hazardous waste and worker exposure. Transparent reporting of materials, processes, and negative results will accelerate learning across the field and prevent duplicative risk.

Finally, the patient perspective matters. Tolerability of injections, expectations regarding weight change, and concerns about "gene" therapies influence adherence. Early and open communication about reversible versus permanent mechanisms, monitoring plans, and contingency protocols builds trust[52]. Addressing these translational and ethical dimensions is as vital as the underlying biology for bringing adipose-targeted nanotherapies to people with obesity-associated T2D.

7. Clinical Translation and Trial Design Strategies for Nanotechnology-Enabled Browning

Clinical development should proceed in staged steps that derisk biology, formulation, and safety in parallel. First-in-human studies can enroll adults with insulin-resistant obesity and subclinical dysglycemia or established T2D on stable background therapy[53]. A single-ascending dose phase emphasizes safety, pharmacokinetics, and depot biodistribution using noninvasive imaging; adaptive features allow image-guided escalation to reach predefined thermogenic thresholds without hemodynamic perturbation. Multiple-ascending dose cohorts then assess durability, re-dosing intervals, and interactions with standard-of-care agents such as metformin or GLP-1/GIP receptor agonists[53].

Primary pharmacodynamic endpoints should include quantitative imaging of thermogenesis in preselected depots (e.g., supraclavicular, axillary, paraspinal) and indirect calorimetry–derived resting energy expenditure under controlled ambient temperature. Key clinical endpoints span fasting glucose, HbA1c, continuous glucose monitoring metrics, insulin dose (if applicable), and validated insulin sensitivity indices. Safety endpoints include ambulatory heart rate and blood pressure, arrhythmia surveillance, and laboratory panels assessing hepatic and renal function. Patient-reported outcomes like appetite, cold sensitivity, and fatigue add context[54].

Formulation-specific considerations guide dosing. For nucleic acid LNPs, transient transgene expression suggests dosing every 2–6 weeks with monitoring for anti-lipid antibodies; for polymeric sustained-release depots, monthly or quarterly injections may suffice[54]. Depot targeting can be enhanced via subcutaneous administration over selected regions, leveraging lymphatic trafficking and local vascular access. Cold acclimation protocols should be standardized or avoided to reduce variability in baseline BAT activity.

Phase 2 programs must demonstrate additive benefit beyond weight loss, specifically improved glycemic control and insulin sensitivity at weight-matched comparisons. Stratified analyses can test whether visceral adiposity or baseline BAT activity predicts response[55]. Drug–device combinations, such as ultrasound-triggered release under real-time thermography, warrant exploratory cohorts. Interim analyses use Bayesian decision rules linked to imaging and glycemic endpoints to optimize dose and schedule[55].

Ultimately, registrational trials will need to show durable improvement in glycemic control and cardiometabolic risk markers with an acceptable safety profile, positioning browning nanotherapies as adjuncts to incretins, SGLT2 inhibitors, and lifestyle intervention. Clear patient selection criteria, rigorous biomarker integration, and pragmatic endpoints will convert the promise of nanotechnology-enabled thermogenesis into tangible clinical benefit for people with obesity-associated T2D.

CONCLUSIONS

Adipose tissue browning offers a mechanistically distinct path to treat obesity-associated T2D by increasing energy expenditure and restoring adipose endocrine health. Nanotechnology addresses long-standing barriers to browning therapeutics by enabling depot targeting, controlled release, and efficient intracellular delivery of both small molecules and nucleic acids, while supporting combination strategies that engage adipocytes and the adipose immune niche. Progress in imaging and biomarkers now allows precise, noninvasive monitoring of thermogenic activation and its metabolic consequences, creating a credible bridge from mechanism to clinical outcome. Nevertheless, translation will depend on rigorous safety evaluation, manufacturability, and ethical clinical deployment that complements rather than replaces proven standards of care. With thoughtful engineering, careful trial design, and patient-centered implementation, nanotechnology-enabled browning can move from concept to clinic as an adjunctive approach that improves insulin sensitivity and glycemic control while minimizing systemic side effects.

REFERENCES

1. AbdlWhab, H.M., Al-Saffar, A., Mahdi, O.A., Alameri, R.B.: The impact of insulin resistance and glycaemic control on insulin-like growth factor-1 in patients with type 2 diabetes: a cross-sectional study. Clin. Diabetes Endocrinol. 10, 36 (2024). https://doi.org/10.1186/s40842-024-00202-8
2. Alzaid, F., Fagherazzi, G., Riveline, J.-P., Bahman, F., Al-Rashed, F., Al-Mulla, F., Ahmad, R.: Immune cell–adipose tissue crosstalk in metabolic diseases with a focus on type 1 diabetes. Diabetologia. 68, 1616–1631 (2025). https://doi.org/10.1007/s00125-025-06437-z
3. Ashley, L., Robb, K.A., O'Connor, D.B., Platt, R., Price, M., Robinson, O., Travis, E., Lipscombe, L., Ajjan, R., Birch, R.: Increased Breast and Colorectal Cancer Risk in Type 2 Diabetes: Awareness Among Adults With and Without Diabetes and Information Provision on Diabetes Websites. Ann. Behav. Med. Publ. Soc. Behav. Med. 57, 386–398 (2023). https://doi.org/10.1093/abm/kaac068
4. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
5. Chakraborty, S., Verma, A., Garg, R., Singh, J., Verma, H.: Cardiometabolic Risk Factors Associated With Type 2 Diabetes Mellitus: A Mechanistic Insight. Clin. Med. Insights Endocrinol. Diabetes. 16, 11795514231220780 (2023). https://doi.org/10.1177/11795514231220780
6. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250

7. Auger, C., Kajimura, S.: Adipose Tissue Remodeling in Pathophysiology. Annu. Rev. Pathol. Mech. Dis. 18, 71–93 (2023). https://doi.org/10.1146/annurev-pathol-042220-023633
8. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov. Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
9. Ikpozu, E.N., Offor, C.E., Igwenyi, I.O., Obaroh, I.O., Ibiam, U.A., Ukaidi, C.U.A.: RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. Diab. Vasc. Dis. Res. 22, 14791641251334726 (2025). https://doi.org/10.1177/14791641251334726
10. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., De Campos, O.C., Udeozor, P.A., Nfona, S.O., Lawal, B., Alum, E.U.: Modulation of Lipogenesis by Tetracarpidium conophorum Nuts via SREBP-1/ACCA-1/FASN Inhibition in Monosodium-Glutamate-Induced Obesity in Rats. Nat. Prod. Commun. 20, 1934578X251344035 (2025). https://doi.org/10.1177/1934578X251344035
11. Uti, D.E., Atangwho, I.J., Eyong, E.U., Umoru, G.U., Egbung, G.E., Nna, V.U., Udeozor, P.A.: African walnuts attenuate ectopic fat accumulation and associated peroxidation and oxidative stress in monosodium glutamate-obese Wistar rats. Biomed. Pharmacother. 124, 109879 (2020). https://doi.org/10.1016/j.biopha.2020.109879
12. Al Tahan, M.A., Al-Khattawi, A., Russell, C.: Oral peptide delivery Systems: Synergistic approaches using polymers, lipids, Nanotechnology, and needle-based carriers. J. Drug Deliv. Sci. Technol. 112, 107205 (2025). https://doi.org/10.1016/j.jddst.2025.107205
13. Awlqadr, F.H., Majeed, K.R., Altemimi, A.B., Hassan, A.M., Qadir, S.A., Saeed, M.N., Faraj, A.M., Salih, T.H., Abd Al-Manhel, A.J., Najm, M.A.A., Tsakali, E., Van Impe, J.F.M., Abd El-Maksoud, A.A., Abedelmaksoud, T.G.: Nanotechnology-based herbal medicine: Preparation, synthesis, and applications in food and medicine. J. Agric. Food Res. 19, 101661 (2025). https://doi.org/10.1016/j.jafr.2025.101661
14. Magadani, R., Ndinteh, D.T., Roux, S., Nangah, L.P., Atangwho, I.J., Uti, D.E., Alum, E.U., Egba, S.I.: Cytotoxic Effects of Lecaniodiscus Cupanioides (Planch.) Extract and Triterpenoids-derived Gold Nanoparticles On MCF-7 Breast Cancer Cell Lines. Anti-Cancer Agents Med. Chem. Former. Curr. Med. Chem. - Anti-Cancer Agents. 25, 841–850 (2025). https://doi.org/10.2174/0118715206325529241004064307
15. Atangwho, I.J., Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
16. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
17. Abbasi, H., Kouchak, M., Mirveis, Z., Hajipour, F., Khodarahmi, M., Rahbar, N., Handali, S.: What We Need to Know about Liposomes as Drug Nanocarriers: An Updated Review. Adv. Pharm. Bull. 13, 7–23 (2023). https://doi.org/10.34172/apb.2023.009
18. Alum, E.U., Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Alum, B.N., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
19. Das, S.S., Bharadwaj, P., Bilal, M., Barani, M., Rahdar, A., Taboada, P., Bungau, S., Kyzas, G.Z.: Stimuli-Responsive Polymeric Nanocarriers for Drug Delivery, Imaging, and Theragnosis. Polymers. 12, 1397 (2020). https://doi.org/10.3390/polym12061397
20. Goyal, S., Thirumal, D., Rana, J., Gupta, A.K., Kumar, A., Babu, M.A., Kumar, P., Sindhu, R.K.: Chitosan based nanocarriers as a promising tool in treatment and management of inflammatory diseases. Carbohydr. Polym. Technol. Appl. 7, 100442 (2024). https://doi.org/10.1016/j.carpta.2024.100442
21. Anwar, D.M., Hedeya, H.Y., Ghozlan, S.H., Ewas, B.M., Khattab, S.N.: Surface-modified lipid-based nanocarriers as a pivotal delivery approach for cancer therapy: application and recent advances in targeted cancer treatment. Beni-Suef Univ. J. Basic Appl. Sci. 13, 106 (2024). https://doi.org/10.1186/s43088-024-00566-x
22. Dash, P., Piras, A.M., Dash, M.: Cell membrane coated nanocarriers - an efficient biomimetic platform for targeted therapy. J. Controlled Release. 327, 546–570 (2020). https://doi.org/10.1016/j.jconrel.2020.09.012
23. George Joy, J., Sharma, G., Kim, J.-C.: Tailoring polymeric nanocarriers for hypoxia-specific drug release: Insights into design and applications in clinics. Chem. Eng. J. 496, 153978 (2024). https://doi.org/10.1016/j.cej.2024.153978
24. Gui, K., Zhang, X., Chen, F., Ge, Z., Zhang, S., Qi, X., Sun, J., Yu, Z.: Lipid-polymer nanoparticles with CD133 aptamers for targeted delivery of all-trans retinoic acid to osteosarcoma initiating cells. Biomed. Pharmacother. Biomedecine Pharmacother. 111, 751–764 (2019). https://doi.org/10.1016/j.biopha.2018.11.118

25. Kangarshahi, B.M., Naghib, S.M.: Nanogenosensors based on aptamers and peptides for bioelectrochemical cancer detection: an overview of recent advances in emerging materials and technologies. Discov. Appl. Sci. 6, 47 (2024). https://doi.org/10.1007/s42452-024-05681-z
26. Oberhaus, F.V., Frense, D., Beckmann, D.: Immobilization Techniques for Aptamers on Gold Electrodes for the Electrochemical Detection of Proteins: A Review. Biosensors. 10, 45 (2020). https://doi.org/10.3390/bios10050045
27. Ogunmolasuyi, A.M., Fogel, R., Hoppe, H., Goldring, D., Limson, J.: A microfluidic paper analytical device using capture aptamers for the detection of PfLDH in blood matrices. Malar. J. 21, 174 (2022). https://doi.org/10.1186/s12936-022-04187-6
28. Du, J., Lane, L.A., Nie, S.: Stimuli-Responsive Nanoparticles for Targeting the Tumor Microenvironment. J. Control. Release Off. J. Control. Release Soc. 219, 205–214 (2015). https://doi.org/10.1016/j.jconrel.2015.08.050
29. Hou, J., Xue, Z., Chen, Y., Li, J., Yue, X., Zhang, Y., Gao, J., Hao, Y., Shen, J.: Development of Stimuli-Responsive Polymeric Nanomedicines in Hypoxic Tumors and Their Therapeutic Promise in Oral Cancer. Polymers. 17, 1010 (2025). https://doi.org/10.3390/polym17081010
30. Wang, T., Liu, Y., Wu, Q., Lou, B., Liu, Z.: DNA nanostructures for stimuli-responsive drug delivery. Smart Mater. Med. 3, 66–84 (2022). https://doi.org/10.1016/j.smaim.2021.12.003
31. Wells, C.M., Harris, M., Choi, L., Murali, V.P., Guerra, F.D., Jennings, J.A.: Stimuli-Responsive Drug Release from Smart Polymers. J. Funct. Biomater. 10, 34 (2019). https://doi.org/10.3390/jfb10030034
32. Yang, J., des Rieux, A., Malfanti, A.: Stimuli-Responsive Nanomedicines for the Treatment of Non-cancer Related Inflammatory Diseases. ACS Nano. 19, 15189–15219 (2025). https://doi.org/10.1021/acsnano.5c00700
33. Zahran, N.H., Abu-Elsaoud, A.M., Mohamed, A.S., Marie, O.M.: Nanoparticle-Delivered Rutin Prevents Metabolic and Oxidative Imbalance in Obesity Triggered by a High-Fat Diet: In Vivo and In Silico Studies. Biomedicines. 13, 2106 (2025). https://doi.org/10.3390/biomedicines13092106
34. Lima, J.F., Cerqueira, L., Figueiredo, C., Oliveira, C., Azevedo, N.F.: Anti-miRNA oligonucleotides: A comprehensive guide for design. RNA Biol. 15, 338–352 (2018). https://doi.org/10.1080/15476286.2018.1445959
35. Corvera, S.: Cellular Heterogeneity in Adipose Tissues. Annu. Rev. Physiol. 83, 257–278 (2021). https://doi.org/10.1146/annurev-physiol-031620-095446
36. Auger, C., Kajimura, S.: Detouring adrenergic stimulation to induce adipose thermogenesis. Nat. Rev. Endocrinol. 17, 579–580 (2021). https://doi.org/10.1038/s41574-021-00546-6
37. Witika, B.A., Makoni, P.A., Matafwali, S.K., Chabalenge, B., Mwila, C., Kalungia, A.C., Nkanga, C.I., Bapolisi, A.M., Walker, R.B.: Biocompatibility of Biomaterials for Nanoencapsulation: Current Approaches. Nanomaterials. 10, 1649 (2020). https://doi.org/10.3390/nano10091649
38. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Nat. Prod. Commun. 20, 1934578X251323393 (2025). https://doi.org/10.1177/1934578X251323393
39. Ocloo, A., Dongdem, J.T.: Mitochondria as Pharmacological Targets: The Discovery of Novel Anti-Obesity Mitochondrial Uncouplers from Africa's Medicinal Plants. Afr. J. Tradit. Complement. Altern. Med. 9, 256–259 (2011). https://doi.org/10.4314/ajtcam.v9i2.11
40. Ashrafizadeh, M., Delfi, M., Zarrabi, A., Bigham, A., Sharifi, E., Rabiee, N., Paiva-Santos, A.C., Kumar, A.P., Tan, S.C., Hushmandi, K., Ren, J., Zare, E.N., Makvandi, P.: Stimuli-responsive liposomal nanoformulations in cancer therapy: Pre-clinical & clinical approaches. J. Controlled Release. 351, 50–80 (2022). https://doi.org/10.1016/j.jconrel.2022.08.001
41. Kevadiya, B.D., Woldstad, C., Ottemann, B.M., Dash, P., Sajja, B.R., Lamberty, B., Morsey, B., Kocher, T., Dutta, R., Bade, A.N., Liu, Y., Callen, S.E., Fox, H.S., Byrareddy, S.N., McMillan, J.M., Bronich, T.K., Edagwa, B.J., Boska, M.D., Gendelman, H.E.: Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. Theranostics. 8, 256–276 (2018). https://doi.org/10.7150/thno.22764
42. Petrovic, S., Bita, B., Barbinta-Patrascu, M.-E.: Nanoformulations in Pharmaceutical and Biomedical Applications: Green Perspectives. Int. J. Mol. Sci. 25, 5842 (2024). https://doi.org/10.3390/ijms25115842
43. Ricci, M., De Feo, M.S., Granese, G.M., Frantellizzi, V., Carabellese, B., Lubrano, E., Cimini, A.: 18F-FDG PET/CT technology for the assessment of brown adipose tissue: an updated review. Expert Rev. Med. Devices. 20, 1143–1156 (2023). https://doi.org/10.1080/17434440.2023.2283618
44. Ebbini, E.S., Simon, C., Liu, D.: Real-time Ultrasound Thermography and Thermometry. IEEE Signal Process. Mag. 35, 166–174 (2018). https://doi.org/10.1109/MSP.2017.2773338
45. Ingraham, K.A., Ferris, D.P., David Remy, C.: Using wearable physiological sensors to predict energy expenditure. IEEE Int. Conf. Rehabil. Robot. Proc. 2017, 340–345 (2017). https://doi.org/10.1109/ICORR.2017.8009270

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

46. Wolfram, J., Zhu, M., Yang, Y., Shen, J., Gentile, E., Paolino, D., Fresta, M., Nie, G., Chen, C., Shen, H., Ferrari, M., Zhao, Y.: Safety of nanoparticles in medicine. Curr. Drug Targets. 16, 1671–1681 (2015). https://doi.org/10.2174/1389450115666140804124808
47. Awlqadr, F.H., Altemimi, A.B., Qadir, S.A., Hama Salih, T.A., Alkanan, Z.T., AlKaisy, Q.H., Mohammed, O.A., Hesarinejad, M.A.: Emerging trends in nano-sensors: A new frontier in food safety and quality assurance. Heliyon. 11, e41181 (2025). https://doi.org/10.1016/j.heliyon.2024.e41181
48. Bilia, A.R., Bergonzi, M.C.: The G115 standardized ginseng extract: an example for safety, efficacy, and quality of an herbal medicine. J. Ginseng Res. 44, 179–193 (2020). https://doi.org/10.1016/j.jgr.2019.06.003
49. Operti, M.C., Bernhardt, A., Sincari, V., Jager, E., Grimm, S., Engel, A., Hruby, M., Figdor, C.G., Tagit, O.: Industrial Scale Manufacturing and Downstream Processing of PLGA-Based Nanomedicines Suitable for Fully Continuous Operation. Pharmaceutics. 14, 276 (2022). https://doi.org/10.3390/pharmaceutics14020276
50. Easley, R., Van Duyne, R., Coley, W., Guendel, I., Dadgar, S., Kehn-Hall, K., Kashanchi, F.: Chromatin dynamics associated with HIV-1 Tat-activated transcription. Biochim. Biophys. Acta BBA - Gene Regul. Mech. 1799, 275–285 (2010). https://doi.org/10.1016/j.bbagrm.2009.08.008
51. 4dm1n_diversatechnologies: Overcoming regulatory hurdles in clinical translation of nanomedicine, https://www.diversatechnologies.com/overcoming-regulatory-hurdles-in-clinical-translation-of-nanomedicine/, (2025)
52. Baryakova, T.H., Pogostin, B.H., Langer, R., McHugh, K.J.: Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat. Rev. Drug Discov. 22, 387–409 (2023). https://doi.org/10.1038/s41573-023-00670-0
53. Tian, X., Wang, L., Zhang, L., Chen, X., Wang, W., Zhang, K., Ge, X., Luo, Z., Zhai, X., Shao, H.: New discoveries in therapeutic targets and drug development pathways for type 2 diabetes mellitus under the guidance of precision medicine. Eur. J. Med. Res. 30, 450 (2025). https://doi.org/10.1186/s40001-025-02682-5
54. DePasquale, H., DeLucenay, A., Ahmed-Sarwar, N.: Correlation of HbA1c and Continuous Glucose Monitor Time in Range. J. Pharm. Technol. JPT Off. Publ. Assoc. Pharm. Tech. 87551225251348832 (2025). https://doi.org/10.1177/87551225251348832
55. Shang, C., Yuan, M., Wang, Y., Wang, Y., Bao, W., Zeng, S., Zhang, D., Liu, P., Sun, L.: Association Between Visceral Obesity and Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Retrospective Study. Diabetes Metab. Syndr. Obes. 17, 2869–2880 (2024). https://doi.org/10.2147/DMSO.S470836

CITE AS: Wambui Kibibi J. (2026). Nanotechnology-Driven Modulation of Adipose Tissue Browning: Therapeutic Implications for Obesity-Associated Type 2 Diabetes. NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES.
https://doi.org/10.59298/NIJRMS/2026/7.1.8794